U.S. Patent Protection Watch List Doesn’t Match PhRMA’s Wish List

U.S. Trade Representative places 10 countries on its “priority watch” list, including China and India, and 27 on its “watch list,” including Canada and Turkey; PhRMA requested that India and Turkey be put on the higher “priority foreign country” list and Canada be moved up to the priority watch list.

The Pharmaceutical Research and Manufacturers of America failed to convince the Office of the U.S. Trade Representative to elevate India, Turkey and Canada on its lists of countries that do not provide sufficient protection of intellectual property rights.

The USTR’s 2014 Special 301 Report, released on April 30, places 10 countries on its “Priority Watch List” and 27 countries on its “Watch List.” The annual report identifies U.S. trading partners that USTR has determined provide inadequate protection of IP rights or deny fair and equitable market access

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

More from Pink Sheet